For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.

The new space is a free community service meant to help healthcare entrepreneurs connect with potential funders.

As measles cases surge to record levels in the U.S., Health and Human Services Secretary Robert F. | As measles cases surge ...

The United Kingdom is establishing a new biosecurity center designed to improve research into potentially pandemic-causing ...

On May 6, Arcutis reported first-quarter results showed loss of 20 cents a share, which slightly beat estimates. Its sales ...

I-Mab (NASDAQ:IMAB) said on Thursday that it has signed an agreement to acquire Bridge Health Biotech. As part of the deal, I-Mab will provide an initial payment of $1.8M to Bridge Health shareholders ...

In the first 6 months of 2025, 385 employees resigned from the Center for Drug Evaluation and Research, compared with under ...

Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future ...

Brisbane-based biotech company Eclipse Ingredients has launched publicly with $7.2 million in funding after navigating a long ...

Regulatory upheaval in the US and a venture capital drought are dampening investor appetites, but there are still diamonds in ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives, namely ...

Over 30 million people in Europe live with a rare disease. Most of them still lack access to accurate diagnosis or treatment ...